Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Gun Min Kim

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

G.M. Kim1, H.D. Koh1, J.H. Kim1, B. Park2, Y.U. Cho2, S.I. Kim2, H.S. Park2, J.Y. Kim2, M.J. Kim2, J.H. Jeong1, J. Sohn3

Author affiliations

  • 1 Division Of Medical Oncology, Department Of Internal Medicine, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 2 Department Of Surgery, Yonsei University College of Medicine, Seoul/KR
  • 3 Division Of Medical Oncology, Department Of Internal Medicine, Yonsei University College of Medicine, Seoul/KR
More

Resources

Abstract 2990

Background

The presence of pretreatment lymphopenia or high NLR (neutrophil-lymphocyte ratio) has been reported as poor prognostic factor in breast cancer. Here, we investigated whether baseline lymphocyte counts and NLR are associated with overall survival (OS), breast cancer specific survival (BCSS), and distant recurrence free survival (DRFS) in large early breast cancer (EBC) patient cohort.

Methods

We reviewed demographic, clinical, pathologic, and survival data from Yonsei Breast Cancer Center Registry. Patients who underwent surgery with stage I-III EBC at the Yonsei Cancer Center between 2006 and 2015 were included. Baseline complete blood counts data were collected from electronic medical records system. Multivariable regression models adjusted for age, stage, neoadjuvant/adjuvant chemotherapy use, subtype were used to evaluate associations between baseline absolute lymphocyte count (ALC) and OS/BCSS/DRFS.

Results

A total of 5,785 stage I–III EBC patients were underwent breast surgery from 2006 to 2015; 533 patients were excluded due to lack of complete data (n = 262) and the diagnosis of second primary cancer (n = 270). Median follow up duration was 72.73 months (95% confidence interval (CI), 73.85-75.64). Of 5,252 eligible patients, only 159 (3.0%) had baseline lymphopenia (ALC < 1,000/mL). The incidence of baseline lymphopenia was similar among age group, stage, and subtype, but patients with HBsAg (+) showed higher baseline lymphopenia than HBV negative patients (7.7% vs. 2.9%, p = <0.001). In univariate analysis, baseline lymphopenia was significantly associated with poor OS, BCSS and DRFS. In multivariable analysis, baseline lymphopenia predicted lower DRFS [HR 0.502; 95% CI, 0.307–0.820]. The prognostic significance of baseline lymphopenia regarding to DRFS was highest in HER2 positive subtype.Table: 196P

Baseline demographics

All Patients (n = 5,252)Baseline Lymphopenia (n = 158)No Baseline Lymphopenia (n = 5,094)
Age
Median (Range)50 (19-92)48 (31-77)50 (19-92)
TNM Stage
I2672 (50.9)81 (51.3)2591 (50.9)
II1890 (36)53 (33.5)1837 (36.1)
III450 (8.6)18 (11.4)432 (8.5)
Subtype
ER+/HER2-3286 (62.6)90 (57)3196 (62.7)
ER+/HER2+558 (10.619 (12)539 (10.6)
ER-/HER2+496 (9.4)22 (13.9)474 (9.3)
ER-/HER2-912 (17.4)27 (17.1)885 (17.4)
Neoadjuvant chemotherapy
Yes983 (18.7)124 (78.5)4145 (81.4)
No4269 (81.3)34 (21.5)949 (18.6)
Adjuvant chemotherapy
Yes2957 (56.3)69 (43.7)2226 (43.7)
No2295 (43.7)89 (56.3)2868 (56.3)
Radiation therapy
Yes3755 (71.5)49 (31)1448 (28.4)
No1497 (28.5)109 (69)3646 (71.6)
Endocrine therapy
Yes3799 (72.3)108 (68.4)3691 (72.5)
No1453 (27.7)50 (31.6)1403 (27.5)
HBsAg test
Positive182 (3.5)14 (8.9)168 (3.3)
Negative4419 (84.1)126 (79.7)4293 (84.3)
Unknown651 (12.4)18 (11.4)633 (12.4)
Baseline Lymphopenia
Yes158 (3)
No5094 (97)

Conclusions

Baseline lymphocyte counts predicted distant recurrence in early breast cancer.

Clinical trial identification

Legal entity responsible for the study

Gun Min Kim.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings